Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LNP-LinearDNA canine cancer vaccine
- Development stage
- Unknown
- Lead developer
- Applied DNA Sciences
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
The LNP-LinearDNA canine cancer vaccine is a therapeutic DNA-based immunotherapy designed for the treatment of canine B-cell lymphoma. Developed by Applied DNA Sciences through its subsidiary LineaRx in partnership with EvviVax, the vaccine utilizes a proprietary cell-free, polymerase chain reaction (PCR)-based manufacturing platform called LinearDNA. This platform produces high-fidelity DNA sequences encoding the telomerase reverse transcriptase (TERT) protein, a biological target often overexpressed in malignant cells. The vaccine is encapsulated in lipid nanoparticles (LNPs), which facilitates delivery into cells via intramuscular administration without the requirement for electroporation. By delivering the genetic sequence for TERT, the vaccine aims to stimulate the dog's immune system to recognize and eliminate TERT-expressing cancer cells, potentially improving survival outcomes in advanced stages of lymphoma.
- Other names
- LinearDNA canine cancer vaccineLNP-LinearDNA TERT vaccineLineaRx canine cancer vaccine
02
Targets
TERT (Telomerase)
Beyond the preview
Go deeper on LNP-LinearDNA canine cancer vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LNP-LinearDNA canine cancer vaccine.